SGT-001 is a gene therapy commercialized by Solid Biosciences, with a leading Phase II program in Duchenne Muscular Dystrophy. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of SGT-001’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for SGT-001 is expected to reach an annual total of $718 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
SGT-001 is under development for the treatment of Duchenne muscular dystrophy (DMD) in adolescents and children. It is administered intravenously in the form of suspension. It is an adeno-associated virus (AAV9) vector-mediated microdystrophin gene therapy that enables the systemic delivery of a synthetic, functional version of the dystrophin gene.
Solid Biosciences Overview
Solid Biosciences, operates as a life science company focused on developing therapies for duchenne muscular dystrophy (DMD). Its offers pipeline product candidates such as SGT-001, a microdystrophin gene therapy administered through adeno-associated virus (AAV) stabilizes dystrophin glycoprotein complex and rescue muscle function; and ANTI-LTBP4. Solid Biosciences has development programs across scientific platforms which include corrective therapies, disease-modifying therapies, disease understanding and assistive devices. The company works in collaboration with University of Massachusetts Medical School, The Duchenne Research Fund, University of Washington, Alex’s Wish. It operates across the US. Solid Biosciences is headquartered in Cambridge, Massachusetts, the US.
The company reported revenues of (US Dollars) US$13.6 million for the fiscal year ended December 2021 (FY2021). The operating loss of the company was US$72.3 million in FY2021, compared to an operating loss of US$88.4 million in FY2020. The net loss of the company was US$72.2 million in FY2021, compared to a net loss of US$88.3 million in FY2020.
For a complete picture of SGT-001’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.